Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — Investor Presentation (January 2022)
37 slides from Hyphens Pharma International's investor presentation, Jan 13, 2022
Slide 1: SGX General Announcement: Corporate Presentation
1/13/22, 12:21 PM General Announcement::CORPORATE PRESENTATION GENERAL ANNOUNCEMENT::CORPORATE PRESENTATION Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Stapled Security No Announcement Details Announcement Title
Slide 2: Hyphens Pharma International Limited Corporate Presentation
HYPHENS PHARMA INTERNATIONAL LIMITED Singapore’s Leading Specialty Pharma & Consumer Healthcare Group 13 JANUARY 2022
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 4: Introduction
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group 7) Hyphens
Slide 5: Company Snapshot
COMPANY SNAPSHOT 18 MAY LISTED ON 2018 THE SGX-CATALIST 4 CORE BUSINESSES 2020 REVENUE 5 COUNTRIES S$123 MILLION 500 PERSONNEL 15 of Hyphens & Ocean Health products are sold every minute!
Slide 6: Our Regional Footprint
OUR REGIONAL FOOTPRINT PHILIPPINES 28 VIETNAM 1802 Our People MALAYSIA 41 SINGAPORE (HQ) 186 INDONESIA 65 1. As at 31 December 2021 2. Based on representative offices and distributors
Slide 7: Our Strategic Focus
OUR STRATEGIC FOCUS ASEAN’s Leading Long-Term Goal Pharmaceuticals & Asia’s No. 1 Consumer Skin Health Healthcare Group Company
Slide 8: Our Business Segments
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group 7) Hyphens
Slide 9: Our Business Segments
OUR BUSINESS SEGMENTS Specialty Pharma Principals Proprietary Brands Medical Hypermart and Digital
Slide 10: Specialty Pharma Principals
SPECIALTY PHARMA PRINCIPALS What We Do 1. We handle specialised products, under exclusive agreements with our principals, mainly from Europe. 2. We register and hold product licenses with local authorities. 3. We promote these products through medical representatives to specialists and GPs.
Slide 11: Our Specialty Pharma Products
OUR SPECIALTY PHARMA PRODUCTS Otorhinolaryngology Orthopaedic Surgery Interventional Cardiology (Biosensors Coronary Stents) Gastroenterology Contrast Media Ophthalmology Family Medicine Allergy Rheumatology Neuroscience & Psychiatry Neonatology Pulmonology
Slide 12: Proprietary Brands
PROPRIETARY BRANDS What We Do 1. We are the product owner, and the world is our market. 2. We engage in product development. 3. We contract manufacture these products, which bear our trademarks.
Slide 13: Brands We Own
BRANDS WE OWN NO. 1 CLINICALLY Brand that I can TOP OF MIND BRAND PROVEN TRUST# By Private Photoaging GOOD VALUE Dermatologists* & Acne Scars for money# *IQVIA 2018 Q3 Survey on Top-of-Mind Awareness on 31 Private Dermatologists in Singapore # 2018 Nielsen Survey – A Comprehensive and Holistic Under
Slide 14: Atopic Dermatitis Range
ATOPIC DERMATITIS RANGE 1 Gentle, Non-Soap Wash 9 1 2 Specially-Formulated Mosquito Repellent for AD 3 Ceramide-Dominant Therapeutic Moisturiser 3 5 7 4 Menthol Gel to Calm & Soothe Itchy Skin 2 4 6 8 5 Maintenance Therapy 6 Triple Protective Action Against Diaper Rash 7 Enriched with Essential Skin
Slide 15: Patent pending in other countries / regions
Patent pending in 13 other countries / regions
Slide 16: Ceradan in China
CERADAN IN CHINA China International Import Exhibition (CIIE) 5-10 Nov 21中国国际进口博览会 1) presentation in Singapore-China Trade & Ceradan Tmall Collaboration with CMA中华医学会 Investment Forum (SCTIF) Global Official Store Medical write-up after pilot study Ceradan海外旗舰店 with Dermatology Branch of Chinese 2)
Slide 17: Facial Skincare Range
FACIAL SKINCARE RANGE ▪ tdf derma formula originates from “Therapeutic Dermatologic Formula” ▪ It is a brand established by Ocean Health for more than 20 years in Singapore and the region ▪ TDF is widely available in Singapore through hospitals, as well as selected dermatologists’ and general practi
Slide 18: Product Portfolio Expansion Through Acquisition
PRODUCT PORTFOLIO EXPANSION THROUGH ACQUISITION Hyphens has acquired the rights, titles and interests in the trademarks of CG 210® for Singapore & Malaysia CG 210® is a globally renowned & patented topical botanical hair growth-promoting agent New brand ownership adds to our Proprietary Brands busin
Slide 19: A Well-Regarded Brand by Consumers
A WELL-REGARDED BRAND BY CONSUMERS *Best-selling fish oil (Omega-3) supplement in major retail pharmacies from 2013-2018 WINNER WINNER WINNER WINNER Guardian Health & Watsons Superbrands Unity Popular Beauty Awards HWB Award Status Choice Award since 2008 since 2007 since 2004 since 2008
Slide 20: Medical Hypermart and Digital
MEDICAL HYPERMART AND DIGITAL What We Do 1. We are a wholesaler of pharmaceutical products and medical supplies. 2. We cater largely to private clinics and pharmacies. 3. We have > 3,000 customers and > 4,000 items in our inventory 4. We also have a B2B e-commerce platform that facilitates 24/7 orde
Slide 21: Medical Hypermart and Digital
MEDICAL HYPERMART AND DIGITAL 1st pharmaceutical wholesaler in Singapore to establish an online platform and capture new digital opportunities Over 1,500 MORE THAN members on our online Medical Hypermart! YEARS HERITAGE BRAND
Slide 22: Latest Developments
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group 7) Hyphens
Slide 23: Acquisition of Novem
1 ACQUISITION OF NOVEM • Singapore-based leading healthcare-focused distributor of pharmaceutical products, nutraceutical products and medical devices • 20-year stable operating track record • >40 brand principals mainly across Europe and Asia • Serves >1,000 active customers including hospitals, po
Slide 24: Rationale
RATIONALE • Strategic opportunity to acquire a portfolio of businesses with a good management team • Financially attractive from a revenue scale and earnings accretion perspective • Gain access to new brand principals, products and customers to enhance and enlarge revenue and profits, and strengthen
Slide 25: Novem Products
NOVEM PRODUCTS Novem’s products cater for a variety of diseases and therapeutic areas such as musculoskeletal, cardiology, ophthalmology and general surgery. Pharmaceuticals Evidence Based Nutraceuticals • Tablet/Capsule/Injectable/Vaccines Novem developed products • Proprietary Brand of Generics •
Slide 26: Novem Products
NOVEM PRODUCTS Medical Devices Visco-supplement Biosurgery KD Intra-articular Gel 2.2% and 2.5% HAppyCross 1.6% (Malaysia Only) HaemoCer (& H Plus) Collatamp G Guardix Sol Glove Port Sodium Hyaluronate Cross-Linked Hyaluronic acid 1.6% + Mannitol 3.5% Plant-based Haemostatic Powder Gentamicin Collag
Slide 27: Licensing Deal of Ustekinumab Biosimilar
2 LICENSING DEAL OF USTEKINUMAB BIOSIMILAR • Exclusive license and supply agreement with DKSH’s subsidiary, Favorex Pte Ltd • To commercialise in Singapore, Malaysia & the Philippines • Proposed Ustekinumab biosimilar, which is undergoing clinical studies, is a human monoclonal antibody for the trea
Slide 28: E-pharmacy Business
3 BUSI NESS 1ST I N SI NG APO RE LI FE CYCLE G RO WTH TO BE G RAN TE D E-PHARMACY EAR LY LICENSE TI M E SI NCE JAN 2021 >100 CLI NI CS HAV E SI G NED UP
Slide 29: Business Outlook
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group 7) Hyphens
Slide 30: Investing for Growth
INVESTING FOR GROWTH 1. Investment in Proprietary Brands 2. Internationalisation 3. Going Digital 4. Strengthen Specialty Pharma Portfolio 5. Acquisitions Challenges : COVID-19
Slide 31: Financials
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group 7) Hyphens
Slide 32: Revenue and Profit After Tax
Revenue (S$’m) Profit After Tax (S$’m) 6.5 6.2 120.9 119.4 123.7 6.1 112.7 5.4 5.4 92.9 FY2017 FY2018 FY2019 FY2020 9M2021 FY2017 FY2018* FY2019 FY2020 9M2021 * Incl IPO exp S$0.9m
Slide 33: Maintaining Dividend Policy
MAINTAINING DIVIDEND POLICY Commitment to maintain dividend policy to pay at least 30% of its net profits attributable to shareholders, subject to the Board’s approval. S$’000 Dividend Yield* Div / NP FY2020 0.62 cents 2.1% 30.2% FY2019 1 cent 3.3% 46.0% FY2018 0.55 cents 1.8% 30.5% * Yield is compu
Slide 34: Research Reports
RESEARCH REPORTS 9 CGSCIMB S Pharmaceuticals | Singapore | January 6, 2022 ariah Compliant Company Note [ Singapore ADD finivation, Consensus ratings" Buy HoldO Seto Curent price 350255 Target price $30.36 Prevous target ss Upidonnside 22.0% CGS-CINB / Consensus 38% Reuters: HYPHSI Bloomberg HYP SP.
Slide 35: Conclusion
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group 7) Hyphens
Slide 36: Key Strengths
KEY STRENGTHS Singapore’s leading specialty pharmaceutical and consumer healthcare groups 1 with an established presence in ASEAN 2 Strong regulatory capabilities with high barriers to entry 3 Portfolio of pharmaceutical products, with strong principal relationships 4 Ownership of a range of proprie
Slide 37: Hyphens Pharma International Limited contact details
Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphensgroup.com
Hyphens Pharma International — Investor Presentation (January 2022) on 6ix